• 1. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Recent Advances in the Study of 3-Pyrazol-1-yl-benzylamine Hydrochloride (CAS: 608515-39-5)

3-Pyrazol-1-yl-benzylamine Hydrochloride (CAS: 608515-39-5) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyrazole and benzylamine functional groups, has been the subject of recent studies due to its potential applications in drug discovery and development. The unique structural features of this molecule make it a promising candidate for modulating various biological targets, including kinases and GPCRs, which are critical in numerous disease pathways.

Recent research has focused on the synthesis and optimization of 3-Pyrazol-1-yl-benzylamine Hydrochloride to enhance its pharmacological properties. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits potent inhibitory activity against specific kinase targets involved in cancer progression. The study utilized a combination of computational modeling and in vitro assays to elucidate the binding mechanisms and structure-activity relationships (SAR) of the compound. These findings provide a foundation for further development of kinase inhibitors based on this scaffold.

In addition to its kinase inhibitory properties, 3-Pyrazol-1-yl-benzylamine Hydrochloride has shown promise in the modulation of GPCRs. A recent preprint on bioRxiv (2024) highlighted its affinity for certain serotonin receptors, suggesting potential applications in neuropharmacology. The study employed high-throughput screening and molecular dynamics simulations to identify the compound's interactions with receptor binding sites. These insights could pave the way for novel therapeutics targeting neurological disorders such as depression and anxiety.

The pharmacokinetic profile of 3-Pyrazol-1-yl-benzylamine Hydrochloride has also been investigated in preclinical models. A 2023 study in the European Journal of Pharmaceutical Sciences reported favorable absorption and distribution characteristics, along with moderate metabolic stability. These properties are crucial for advancing the compound into further stages of drug development. However, challenges such as optimizing bioavailability and minimizing off-target effects remain areas of active research.

Future directions for research on 3-Pyrazol-1-yl-benzylamine Hydrochloride include exploring its potential in combination therapies and expanding its application to other disease models. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications. As the understanding of this compound's mechanisms deepens, it holds the potential to become a cornerstone in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)